Entrada Therapeutics (NASDAQ:TRDA) (NASDAQ:TRDA) is a clinical-stage biotechnology company dedicated to developing therapies that overcome one of the greatest barriers in modern medicine: delivering large biologic molecules inside cells. The company’s proprietary CellPorter™ platform is designed to facilitate the intracellular delivery of proteins, peptides and nucleic acids, enabling a new class of treatments for genetic diseases, oncology and other indications that have proven refractory to traditional small-molecule and antibody drugs.
Using its CellPorter™ technology, Entrada Therapeutics engineers bespoke delivery vehicles that can transport therapeutic cargo across cell membranes without relying on viral vectors. This approach is intended to expand the reach of biologics by targeting intracellular processes, offering the potential to correct the underlying cause of disease at the molecular level. The platform has supported multiple preclinical programs and has progressed at least one lead candidate into early-phase clinical trials, focusing on rare enzyme-deficiency disorders.
Since its founding in 2018 as a spin-out from leading academic research, Entrada has built a pipeline that spans rare metabolic conditions and immuno-oncology. The company operates from its headquarters in Cambridge, Massachusetts, and maintains collaborative research partnerships in Europe and Asia to advance discovery and development efforts. By combining cell-penetrating delivery systems with cutting-edge molecular payloads, Entrada aims to address high unmet medical needs in both inherited and acquired diseases.
Entrada’s leadership team brings together seasoned executives and scientists with extensive experience in biologics development, regulatory strategy and commercialization. The board and management have backgrounds at major pharmaceutical and biotech companies, as well as top academic institutions, ensuring a blend of scientific rigor and industry know-how. Under their guidance, Entrada continues to expand its technology platform and advance its pipeline toward meaningful clinical milestones.
